Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Saint-Cloud – page 17

3 344 clinical trials in Saint-Cloud, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Saint-Cloud at a glance
3 344
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

3 344 trials in Saint-Cloud

Open in trial search

Osteosarcoma

Recruiting

Cabozantinib Maintenance Therapy vs Best Supportive Care in Osteosarcoma Patients in Complete Remission or with Residual Disease after First‑Line Chemotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Institut Gustave Roussy

Oesophageal adenocarcinoma

Recruiting

Study of PF-08634404 with chemotherapy drug combination in previously untreated patients with locally advanced or metastatic gastric and gastroesophageal adenocarcinoma

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Pfizer Inc.

Neoplasm

Recruiting

Study of BMS-986504 alone or in drug combination in adults with advanced or metastatic solid tumors with MTAP deletion

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Interstitial lung disease

Recruiting

Safety, Pharmacokinetics, and Exploratory Efficacy of BI 1015550 and Nerandomilast in Children and Adolescents Aged 2‑17 Years With Fibrosing Interstitial Lung Disease

Investigational
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Nerandomilast
  • Sponsor:Boehringer Ingelheim Espana S.A.

Chronic obstructive pulmonary disease

Recruiting

Efficacy and safety of lunsekimig in adults with inadequately controlled eosinophilic COPD: a randomized, double‑blind, placebo‑controlled trial

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lunsekimig
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Plasma cell myeloma refractory

Recruiting

Phase 3 Study Comparing JNJ-79635322 with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma after 1‑3 Prior Treatments

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:JNJ-79635322
  • Sponsor:Janssen Cilag International

Ovarian cancer recurrent

Recruiting

Rinatabart Sesutecan plus bevacizumab vs standard care as maintenance for recurrent platinum‑sensitive ovarian cancer after second‑line chemotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Genmab A/S

Neuroblastoma

Recruiting

Study of hu14.18K322A with temozolomide and irinotecan in children and adolescents with high‑risk neuroblastoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:hu14.18K322A
  • Sponsor:Renaissance Pharma Limited

Neoplasm+1

Recruiting

Safety and Tolerability of Inhaled KB707 with or without Docetaxel in Patients with Advanced Lung Solid Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Krystal Biotech Inc.

Systemic lupus erythematosus+3

Recruiting

A Phase 3 Study of Enpatoran to Treat Active Cutaneous Lupus in Patients With or Without Systemic Disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Enpatoran hemihydrate
  • Sponsor:Merck Healthcare KGaA

Small cell lung cancer

Recruiting

Phase 2 Study of PF-08634404 with Carboplatin and Etoposide in Adults with Untreated Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Pfizer Inc.

Colorectal cancer+2

Recruiting

Study of RMC-6291 with ivonescimab drug combination in patients with advanced RAS‑mutated solid tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Revolution Medicines Inc.

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Saint-Cloud

What the registry says about research in the country

01 Blood Cancer Research

Innovative trials focusing on lymphoma and multiple myeloma treatments, including studies of novel therapies like duvelisib for T-cell lymphoma and odronextamab for follicular lymphoma.

  • B-Cell Lymphomas
  • Multiple Myeloma
  • T-Cell Lymphomas

Several studies are evaluating combination therapies and comparing new treatment approaches against standard care.

02 Breast Cancer Studies

Comprehensive research into various types of breast cancer, with particular focus on hormone receptor-positive and triple-negative variants. Studies include early detection methods and novel therapeutic combinations.

  • HR+/HER2- Advanced Breast Cancer
  • Triple-Negative Breast Cancer
  • Early-Stage Disease

Trials incorporate innovative approaches like ctDNA monitoring and targeted therapies.

03 Advanced Cancer Therapies

Research focusing on targeted therapies for various advanced cancers, including studies of biliary tract cancer and non-small cell lung cancer treatments.

  • Lung Cancer
  • Biliary Tract Cancer
  • Prostate Cancer

Emphasis on immunotherapy combinations and precision medicine approaches.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.